The EU Commission fines two pharmaceutical companies for a pay-for-delay patent settlement agreement (Teva / Cephalon)

L'Ecluse, Peter; Longeval, Catherine; T'Syen, Koen

Previous article The US FTC charges 2 pharmaceutical companies for the second time with preventing competition in the national market for oxymorphone (Endo / Impax) Next article The EU Commission fines pharmaceutical companies for pay-for-delay agreement (Teva / Cephalon)

26 Nov 2020

The EU Commission fines two pharmaceutical companies for a pay-for-delay patent settlement agreement (Teva / Cephalon)

KEYWORDS

Reference

EU Commission, Teva / Cephalon, Press release, 26 November 2020

On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Peter L’Ecluse
Van Bael & Bellis (Brussels)

Belgium 142 contributions 49253 visits
Catherine Longeval
Van Bael & Bellis (Brussels)

Belgium 46 contributions 23046 visits
Koen T’Syen
Van Bael & Bellis (Brussels)

Belgium 45 contributions 22147 visits

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission fines two pharmaceutical companies for a pay-for-delay patent settlement agreement (Teva / Cephalon), 26 November 2020, e-Competitions Pay-for-delay agreements, Art. N° 98080

Visites 404